A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder
- 5 September 2022
- journal article
- review article
- Published by Springer Nature in Experimental Brain Research
- Vol. 240 (10) , 1-43
Abstract
Intellectual disability (ID) and autism spectrum disorder (ASD) are neurodevelopmental disorders that have become a primary clinical and social concern, with a prevalence of 2–3% in the population. Neuronal function and behaviour undergo significant malleability during the critical period of development that is found to be impaired in ID/ASD. Human genome sequencing studies have revealed many genetic variations associated with ASD/ID that are further verified by many approaches, including many mouse and other models. These models have facilitated the identification of fundamental mechanisms underlying the pathogenesis of ASD/ID, and several studies have proposed converging molecular pathways in ASD/ID. However, linking the mechanisms of the pathogenic genes and their molecular characteristics that lead to ID/ASD has progressed slowly, hampering the development of potential therapeutic strategies. This review discusses the possibility of recognising the common molecular causes for most ASD/ID based on studies from the available models that may enable a better therapeutic strategy to treat ID/ASD. We also reviewed the potential biomarkers to detect ASD/ID at early stages that may aid in diagnosis and initiating medical treatment, the concerns with drug failure in clinical trials, and developing therapeutic strategies that can be applied beyond a particular mutation associated with ASD/ID.Keywords
Funding Information
- DST-SERB (EMR/2016/004795, CRG/2021/000356)
- DBT-STAAG (BT/PR28460/MED/122/169/2020)
This publication has 507 references indexed in Scilit:
- Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agentsTherapeutics and Clinical Risk Management, 2013
- Developmental regulation of GABAergic signalling in the hippocampus of neuroligin 3 R451C knock-in mice: an animal model of AutismFrontiers in Cellular Neuroscience, 2013
- Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic reviewIntensive Care Medicine, 2012
- New perspectives on the biology of fragile X syndromeCurrent Opinion in Genetics & Development, 2012
- Absence of CNTNAP2 Leads to Epilepsy, Neuronal Migration Abnormalities, and Core Autism-Related DeficitsCell, 2011
- FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and AutismCell, 2011
- TSC1/TSC2 signaling in the CNSFEBS Letters, 2011
- The Angelman Syndrome Protein Ube3A Regulates Synapse Development by Ubiquitinating ArcCell, 2010
- Neurofibromin Regulation of ERK Signaling Modulates GABA Release and LearningCell, 2008
- Structural Variation of Chromosomes in Autism Spectrum DisorderThe American Journal of Human Genetics, 2008